Compare IPGP & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPGP | APGE |
|---|---|---|
| Founded | 1990 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.7B |
| IPO Year | 2000 | 2023 |
| Metric | IPGP | APGE |
|---|---|---|
| Price | $107.31 | $78.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 13 |
| Target Price | ★ $131.40 | $109.25 |
| AVG Volume (30 Days) | 406.5K | ★ 1.1M |
| Earning Date | 05-05-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 117.85 | N/A |
| EPS | ★ 0.73 | N/A |
| Revenue | ★ $1,003,777,000.00 | N/A |
| Revenue This Year | $12.18 | N/A |
| Revenue Next Year | $8.44 | N/A |
| P/E Ratio | $158.53 | ★ N/A |
| Revenue Growth | ★ 2.73 | N/A |
| 52 Week Low | $48.59 | $26.20 |
| 52 Week High | $155.82 | $85.04 |
| Indicator | IPGP | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 41.16 | 58.43 |
| Support Level | $105.84 | $73.06 |
| Resistance Level | $141.43 | $81.04 |
| Average True Range (ATR) | 7.13 | 4.66 |
| MACD | -1.39 | 0.86 |
| Stochastic Oscillator | 5.93 | 68.19 |
IPG Photonics Corp is a vertically integrated developer and manufacturer of high-performance fiber lasers, laser and non-laser systems, fiber amplifiers, diode lasers, and related optical components. Its products are used in diverse applications in the manufacturing, automotive, industrial, aerospace, semiconductor, and consumer end markets. The company sells its products globally to original equipment manufacturers (OEMs), system integrators, and end users. Additionally, it manufactures complementary products used with its lasers, including optical delivery cables, fiber couplers, beam switches, optical processing heads, in-line sensors, and chillers. Geographically, the company generates maximum revenue from North America, followed by China, Japan, Germany, and other markets.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.